Our observation that inhibiting EDI3 decreased the viability of HCC1954 cells led us to hypothesize that EDI3 is a potential therapeutic target in ER − HER2 + breast cancers resistant to standard therapy. The gene discussed is ERBB2; the disease is breast cancer.